Biopharmaceutical Capacity Expansion Drives Hygienic Pump Demand
Cell and gene therapy manufacturing capacity is expanding rapidly across North America and Western Europe, and each new facility specifies single-use and hygienic-design pumps validated against strict sterility and cross-contamination requirements that conventional industrial pumps cannot meet. Watson-Marlow and Netzsch have both expanded single-use peristaltic product lines specifically targeting this segment, adding disposable fluid path components that eliminate cleaning validation entirely between production batches. Smaller specialty biotech manufacturers, previously priced out of dedicated hygienic equipment, increasingly find affordable modular options entering the market. The shift is turning pump selection into a regulatory compliance decision as much as a mechanical one.
Market Impact: Adds 12,000 treatment plant upgrades








